AU4766096A - Anti-obesity proteins - Google Patents

Anti-obesity proteins

Info

Publication number
AU4766096A
AU4766096A AU47660/96A AU4766096A AU4766096A AU 4766096 A AU4766096 A AU 4766096A AU 47660/96 A AU47660/96 A AU 47660/96A AU 4766096 A AU4766096 A AU 4766096A AU 4766096 A AU4766096 A AU 4766096A
Authority
AU
Australia
Prior art keywords
obesity proteins
obesity
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU47660/96A
Inventor
Margaret B Basinski
Richard D. Dimarchi
David B Flora
William F. Heath Jr.
James A Hoffmann
Brigitte E Schoner
James E Shields
David L Smiley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/381,049 external-priority patent/US5574133A/en
Priority claimed from US08/381,666 external-priority patent/US5521283A/en
Priority claimed from US08/381,037 external-priority patent/US5563243A/en
Priority claimed from US08/381,034 external-priority patent/US5532336A/en
Priority claimed from US08/381,057 external-priority patent/US5580954A/en
Priority claimed from US08/381,050 external-priority patent/US5563244A/en
Priority claimed from US08/381,370 external-priority patent/US5525705A/en
Priority claimed from US08/381,054 external-priority patent/US5569743A/en
Priority claimed from US08/381,040 external-priority patent/US5552522A/en
Priority claimed from US08/381,163 external-priority patent/US5563245A/en
Priority claimed from US08/381,041 external-priority patent/US5567678A/en
Priority claimed from US08/383,632 external-priority patent/US5569744A/en
Priority claimed from US08/383,649 external-priority patent/US5567803A/en
Priority claimed from US08/383,650 external-priority patent/US5691309A/en
Priority claimed from US08/384,492 external-priority patent/US5594104A/en
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU4766096A publication Critical patent/AU4766096A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU47660/96A 1995-01-31 1996-01-29 Anti-obesity proteins Abandoned AU4766096A (en)

Applications Claiming Priority (39)

Application Number Priority Date Filing Date Title
US381266 1982-05-24
US381057 1989-07-17
US383632 1989-07-24
US38126695A 1995-01-31 1995-01-31
US38104795A 1995-01-31 1995-01-31
US38124795A 1995-01-31 1995-01-31
US38145195A 1995-01-31 1995-01-31
US381370 1995-01-31
US08/381,666 US5521283A (en) 1995-01-31 1995-01-31 Anti-obesity proteins
US08/381,041 US5567678A (en) 1995-01-31 1995-01-31 Anti-obesity proteins
US381666 1995-01-31
US08/381,057 US5580954A (en) 1995-01-31 1995-01-31 Anti-obesity proteins
US381054 1995-01-31
US381047 1995-01-31
US08/381,050 US5563244A (en) 1995-01-31 1995-01-31 Anti-obesity proteins
US08/381,370 US5525705A (en) 1995-01-31 1995-01-31 Anti-obesity proteins
US08/381,054 US5569743A (en) 1995-01-31 1995-01-31 Anti-obesity proteins
US381049 1995-01-31
US381034 1995-01-31
US381050 1995-01-31
US381041 1995-01-31
US381247 1995-01-31
US08/381,049 US5574133A (en) 1995-01-31 1995-01-31 Anti-obesity proteins
US381040 1995-01-31
US381037 1995-01-31
US08/381,037 US5563243A (en) 1995-01-31 1995-01-31 Anti-obesity proteins
US08/381,034 US5532336A (en) 1995-01-31 1995-01-31 Anti-obesity proteins
US08/381,163 US5563245A (en) 1995-01-31 1995-01-31 Anti-obesity proteins
US381163 1995-01-31
US381451 1995-01-31
US08/381,040 US5552522A (en) 1995-01-31 1995-01-31 Anti-obesity proteins
US384492 1995-02-06
US08/383,632 US5569744A (en) 1995-01-31 1995-02-06 Anti-obesity proteins
US08/383,649 US5567803A (en) 1995-01-31 1995-02-06 Anti-obesity proteins
US08/383,650 US5691309A (en) 1995-01-31 1995-02-06 Anti-obesity proteins
US383649 1995-02-06
US08/384,492 US5594104A (en) 1995-01-31 1995-02-06 Anti-obesity proteins
PCT/US1996/000947 WO1996023514A1 (en) 1995-01-31 1996-01-29 Anti-obesity proteins
US383650 2009-03-27

Publications (1)

Publication Number Publication Date
AU4766096A true AU4766096A (en) 1996-08-21

Family

ID=27586325

Family Applications (1)

Application Number Title Priority Date Filing Date
AU47660/96A Abandoned AU4766096A (en) 1995-01-31 1996-01-29 Anti-obesity proteins

Country Status (5)

Country Link
EP (1) EP0836620A1 (en)
JP (1) JPH11501297A (en)
AU (1) AU4766096A (en)
CA (1) CA2211656A1 (en)
WO (1) WO1996023514A1 (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
GB9509164D0 (en) * 1995-05-05 1995-06-28 Smithkline Beecham Plc Novel compounds
WO1997016550A1 (en) * 1995-11-02 1997-05-09 Bristol-Myers Squibb Company Polypeptide fragments derived from the obese gene product
EP0902623A1 (en) * 1996-04-23 1999-03-24 Novo Nordisk A/S Animal feed additives
TR199802534T2 (en) * 1996-06-06 1999-03-22 Smithkline Beecham P.L.C. Leptin (OB Protein) fragmanlar�
AU4582597A (en) * 1996-10-11 1998-05-11 Eli Lilly And Company Therapeutic proteins
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
CA2464277C (en) 2001-10-22 2013-02-05 Amgen, Inc. Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
AU2004274309B2 (en) 2003-09-22 2010-04-08 Msd K.K. Novel piperidine derivative
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc Method of treating men with metabolic and anthropometric disorders
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
EP1892241B1 (en) 2005-05-30 2016-03-30 Msd K.K. Novel piperidine derivative
JPWO2007018248A1 (en) 2005-08-10 2009-02-19 萬有製薬株式会社 Pyridone compounds
EP1921065B1 (en) 2005-08-24 2010-10-20 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
US8227408B2 (en) 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
JPWO2007029847A1 (en) 2005-09-07 2009-03-19 萬有製薬株式会社 Bicyclic aromatic substituted pyridone derivatives
US8293900B2 (en) 2005-09-29 2012-10-23 Merck Sharp & Dohme Corp Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
RU2008119687A (en) 2005-10-21 2009-11-27 Новартис АГ (CH) COMBINATIONS OF ORGANIC COMPOUNDS
CA2627139A1 (en) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. Novel benzoxathiin derivative
KR101318127B1 (en) 2005-11-10 2013-10-16 엠에스디 가부시키가이샤 Aza-substituted spiro derivative
EP2083831B1 (en) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
WO2008047544A1 (en) 2006-09-28 2008-04-24 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
JP5319518B2 (en) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 Indoledione derivative
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US8034782B2 (en) 2008-07-16 2011-10-11 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA3089569C (en) 2007-06-04 2023-12-05 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2264026A4 (en) 2008-03-06 2012-03-28 Msd Kk Alkylaminopyridine derivative
AU2009229860A1 (en) 2008-03-28 2009-10-01 Msd K.K. Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
CA2725143A1 (en) 2008-05-21 2009-11-26 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
CA2930674A1 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2009154132A1 (en) 2008-06-19 2009-12-23 萬有製薬株式会社 Spirodiamine-diarylketoxime derivative
EP2319841A1 (en) 2008-07-30 2011-05-11 Msd K.K. (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP5557845B2 (en) 2008-10-31 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション Novel cyclic benzimidazole derivatives useful as antidiabetic agents
JP2012508242A (en) 2008-11-04 2012-04-05 ニコラオス テザプシディス Leptin compositions and methods for treating progressive cognitive impairment resulting from neurofibrillary tangles and amyloid beta accumulation
WO2010075068A1 (en) 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
EP2379562A1 (en) 2008-12-16 2011-10-26 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
WO2010118384A2 (en) 2009-04-10 2010-10-14 Amylin Pharmaceuticals, Inc. Amylin agonist compounds for estrogen-deficient mammals
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
DK2621519T3 (en) 2010-09-28 2017-10-16 Aegerion Pharmaceuticals Inc Leptin-ABD fusion polypeptides with improved duration of action
JP5728099B2 (en) 2011-02-25 2015-06-03 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Novel cyclic azabenzimidazole derivatives useful as antidiabetic agents
US9527875B2 (en) 2012-08-02 2016-12-27 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
RU2015140066A (en) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. ANTI-DIABETIC BICYCLIC COMPOUNDS
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP6606491B2 (en) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド Ultra high purity agonist of guanylate cyclase C, method for producing and using the same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
RU2021109549A (en) 2014-08-29 2021-05-13 Тес Фарма С.Р.Л. Α-AMINO-β-CARBOXYMUCONATE INHIBITORS of ε-SEMIALDEHYDE-DECARBOXYLASE
AR109950A1 (en) 2016-10-14 2019-02-06 Tes Pharma S R L A-AMINO-b-CARBOXIMUCONIC SEMIAL DEHYDE DECARBOXYLASE ACID INHIBITORS
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
AU2019385644A1 (en) 2018-11-20 2021-06-03 Tes Pharma S.R.L. Inhibitors of α-Amino-β-carboxymuconic acid semialdehyde decarboxylase

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626549A (en) * 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines

Also Published As

Publication number Publication date
WO1996023514A1 (en) 1996-08-08
CA2211656A1 (en) 1996-08-08
EP0836620A1 (en) 1998-04-22
JPH11501297A (en) 1999-02-02

Similar Documents

Publication Publication Date Title
AU4766196A (en) Anti-obesity proteins
AU4774496A (en) Anti-obesity proteins
AU4862096A (en) Anti-obesity proteins
AU4705196A (en) Anti-obesity proteins
AU4774696A (en) Anti-obesity proteins
AU4766096A (en) Anti-obesity proteins
EP0810871A4 (en) Anti-obesity proteins
AU7203496A (en) Novel peptides
AU5181296A (en) Anti-obesity proteins
AU4922497A (en) Interleukin-18-receptor proteins
AU5539596A (en) Anti-obesity agents
AU1115897A (en) Nima interacting proteins
AU4413096A (en) Phenylalanine free proteins
AU4427296A (en) Novel peptide
AU6873596A (en) Allergen-xcd32 fusion proteins
AU7294396A (en) Protein detection
AU4394396A (en) Modified peptides
GB9510830D0 (en) Proteins
AU3804995A (en) Melanoma-associated protein
AU2131195A (en) Prophenins - antibiotic peptides
AU5989696A (en) Tcr vbeta5 peptides
AU4396396A (en) Baby-bathing aid
AU7520396A (en) Abl-interactor protein
AU4843297A (en) Anti-obesity proteins
AU5284296A (en) Immune-evading proteins